Assessing DocuSign (DOCU) Valuation After New AI Assistant Launch And Legal AI Partnerships

DocuSign (DOCU) is back in focus after unveiling an AI contract assistant, new agent tools, and partnerships with legal AI platforms such as Legora and Harvey, directly integrating advanced automation into core agreement workflows.

See our latest analysis for DocuSign.

The recent AI contract assistant launch and partnerships with Harvey and Legora come as DocuSign’s share price, now at US$47.71, shows mixed momentum. The 1-day share price return is 4.86% and the 90-day share price return is 6.45%, but the year-to-date share price return is down 26.43% and the 1-year total shareholder return is down 48.38%. This points to interest around new product news, alongside an overall weak long-term experience for shareholders.

If you are looking beyond DocuSign to see where AI is being built into real products, this is a good moment to check out 62 profitable AI stocks that aren't just burning cash

With the stock at US$47.71 after a difficult multi year shareholder experience, yet trading below the average analyst price target and some estimates of intrinsic value, is this AI push underappreciated, or is future growth already priced in?

Most Popular Narrative: 20.7% Undervalued

At a last close of $47.71 versus a fair value estimate of $60.16 using an 8.5% discount rate, the most followed narrative sees meaningful upside potential tied to agreement driven AI adoption and operating efficiency.

Rollout and ramp-up of the IAM platform, with AI-native features and deep enterprise system integrations, is unlocking significant upsell opportunities as customers migrate from core eSignature to broader agreement management, driving improved ARPU and supporting double-digit future topline growth.

Read the complete narrative.

Curious what sits behind that fair value gap? The narrative leans heavily on recurring revenue, higher margins, and a future earnings multiple that assumes solid execution. The exact growth, profitability and rating needed to bridge from today’s share price to that $60.16 estimate are all laid out in detail.

Result: Fair Value of $60.16 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, recent analyst downgrades and sector wide concerns about AI disrupting pricing power or slowing adoption of DocuSign’s IAM platform could easily challenge that undervalued thesis.

Find out about the key risks to this DocuSign narrative.

Another View: Market Multiple Sends a Mixed Signal

While our DCF model flags DocuSign as trading 64.5% below its future cash flow value, the market is less generous on earnings. At a 30x P/E, the stock sits above the US Software industry at 28.4x and above its own 29x fair ratio, which suggests less margin for error if growth or margins disappoint.

For investors weighing these conflicting signals, the key question is whether the cash flow story or the earnings multiple is the better guide to risk and opportunity from here, or whether it simply points to a bumpier path ahead for returns than either model implies.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of upside potential and clear concerns makes this a stock you will want to assess on your own terms, so take a closer look at the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If DocuSign has sharpened your focus on quality, do not stop here. Broaden your watchlist now so you are not reacting after markets move.

• Target dependable cash generators by scanning companies in the 50 high quality undervalued stocks that pair quality fundamentals with prices below their assessed worth.
• Strengthen your income stream by reviewing the 12 dividend fortresses and spotting stocks that combine higher yields with disciplined payout histories.
• Prioritize resilience by focusing on the 66 resilient stocks with low risk scores, highlighting businesses that score well on financial strength and risk checks before problems appear.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com